Evidence map›Paper›PMID 40368987›Full record

ArticleScientific reports2025

Real-world evidence couples genomic biomarkers with therapeutic outcomes for canine hemangiosarcoma.

Lucas Rodrigues, Kevin Wu, Garrett Harvey, Gerald Post, Aubrey Miller, Abigail Hull, Lindsay Lambert, Christina Lopes, James Zou

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lucas Rodrigues *One Health Company, 530 Lytton Ave, 2nd Floor, Palo Alto, CA, 94301, USA. lucas@fidocure.com.
Kevin Wu *Department of Biomedical Data Science, Stanford University, Stanford, CA, USA.
Garrett HarveyOne Health Company, 530 Lytton Ave, 2nd Floor, Palo Alto, CA, 94301, USA.
Gerald PostOne Health Company, 530 Lytton Ave, 2nd Floor, Palo Alto, CA, 94301, USA.
Aubrey MillerOne Health Company, 530 Lytton Ave, 2nd Floor, Palo Alto, CA, 94301, USA.
Abigail HullOne Health Company, 530 Lytton Ave, 2nd Floor, Palo Alto, CA, 94301, USA.
Lindsay LambertOne Health Company, 530 Lytton Ave, 2nd Floor, Palo Alto, CA, 94301, USA.
Christina LopesOne Health Company, 530 Lytton Ave, 2nd Floor, Palo Alto, CA, 94301, USA.
James ZouDepartment of Biomedical Data Science, Stanford University, Stanford, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Splenic hemangiosarcoma (HSA) is a common canine tumor with histology and genetics analogous to human angiosarcoma (AS), a rare and aggressive malignancy arising from vascular cells. To assess biomarkers and inform therapeutics options, spontaneously arising HSAs were systematically profiled for genetic mutations prior to long-term assessment of patient response to chemotherapy and/or targeted therapy. We leveraged the real-world clinical-genomic data of dogs from the FidoCure

Indexed as

Biomarkers, TumorDog DiseasesHemangiosarcomaSplenic NeoplasmsAnimalsDogsFemaleGenomicsHigh-Throughput Nucleotide SequencingMaleMutationTreatment OutcomeTumor Suppressor Protein p53Biomarkers, TumorTumor Suppressor Protein p53

Identifiers

PMID40368987
PMCPMC12078565

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.